EANS-News: NOXXON Pharma AG announces management changes

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Berlin, Germany, June 28, 2010 (euro adhoc) - NOXXON Pharma AG, Berlin, Germany
announced today that CEO Dr Frank Morich will leave the company effective August
15, 2010 to take up the position Executive Vice President, International
Operations, at Takeda Pharmaceutical Company Limited.

Iain Buchanan, who worked with the Board of Directors since 2007 and later
became a Director of NOXXON Pharma AG , will assume the role of Interim CEO with
effect from September 1, 2010, and will support the board during its search for
a permanent replacement.

Iain has an impressive track record and brings to NOXXON over 30 years of
experience in the pharmaceutical and biotech industry. He comes to NOXXON from
Novexel in Paris where, earlier this year, he was responsible for the sale of
the company to Astra Zeneca. Prior to his role as CEO of Novexel Iain has held
a range of management and business development positions within a number of
companies in the pharmaceutical industry including Vertex, Johnson and Johnson,
Biogen, and Merck & Co.

Dr Walter Wenninger, Chairman of the Board of NOXXON Pharma AG comments: " Under
Frank Morich´s leadership, NOXXON has made the successful transition into a
development stage company with two compounds already in clinical development, an
interesting preclinical pipeline, and future funding secured. The board joins
me in thanking Frank for his achievements and we all wish him well in his new
appointment." He continues: " We are grateful to Iain for his willingness to act
as Interim CEO and are certain his management skills and professional experience
will ensure continuity and future success for NOXXON and its entire dedicated
team."

About NOXXON
Berlin-based NOXXON Pharma AG is a clinical stage biotechnology company focusing
on the development of Spiegelmers® for the treatment of various disease
indications. NOXXON is in possession of a broad patent estate and has access to
a readily scalable GMP production. In addition to its in-house programs, NOXXON
discovers and develops Spiegelmers® in collaboration with partners from the
pharmaceutical industry, including Eli Lilly and Hoffmann La-Roche. The business
strategy of NOXXON is to broaden this range of collaborations through
co-development and licensing agreements for the proprietary clinical and
pre-clinical products. Currently, the company has two compounds in clinical
development. The declared goal of NOXXON is to establish its
oligonucleotide-based drug discovery platform (Spiegelmers®) as the leading
"scaffold" technology to create new chemical entities with superior properties.

Webseite: http://www.noxxon.com

General contact:
Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49-30-726247-100
FAX: + 49-30-726247-225
Email: [email protected]

Further inquiry note:
Marco Scheidler
Tel.: +49 (0) 3641 573-3600
E-Mail: [email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
Leutragraben 1
D-07743 Jena
phone: +49 (0)3641 573 3600
FAX: +49 (0)3641 573 3610
mail: [email protected]
WWW: http://www.dewb-vc.com
sector: Financial & Business Services
ISIN: DE0008041005
indexes:
stockmarkets: free trade: Berlin, Stuttgart, München, Open Market / Entry Standard:
Frankfurt
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print